Dashboard
1
The company has declared negative results in Mar'2025 after 6 consecutive positive quarters
- INTEREST(HY) At CNY 0.06 MM has Grown at 802.61%
- OPERATING PROFIT MARGIN(Q) Lowest at 39.74 %
2
With ROE of 12.05%, it has a attractive valuation with a 1.22 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,511 Million (Small Cap)
10.00
NA
0.71%
-0.67
10.88%
1.01
Revenue and Profits:
Net Sales:
157 Million
(Quarterly Results - Sep 2025)
Net Profit:
51 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.77%
0%
0.77%
6 Months
-20.82%
0%
-20.82%
1 Year
4.09%
0%
4.09%
2 Years
12.01%
0%
12.01%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Hangzhou AGS MedTech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
38.60%
EBIT Growth (5y)
56.97%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
0.25
Tax Ratio
14.89%
Dividend Payout Ratio
37.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
67.58%
ROE (avg)
11.26%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.22
EV to EBIT
3.91
EV to EBITDA
3.75
EV to Capital Employed
1.90
EV to Sales
1.71
PEG Ratio
NA
Dividend Yield
0.60%
ROCE (Latest)
48.48%
ROE (Latest)
12.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
156.90
161.20
-2.67%
Operating Profit (PBDIT) excl Other Income
49.70
77.60
-35.95%
Interest
0.00
0.00
Exceptional Items
-0.30
0.00
Consolidate Net Profit
51.00
73.00
-30.14%
Operating Profit Margin (Excl OI)
316.70%
465.50%
-14.88%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -2.67% vs 14.90% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -30.14% vs 13.35% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
629.90
504.40
24.88%
Operating Profit (PBDIT) excl Other Income
292.30
223.40
30.84%
Interest
0.40
0.30
33.33%
Exceptional Items
2.10
0.40
425.00%
Consolidate Net Profit
293.40
217.20
35.08%
Operating Profit Margin (Excl OI)
448.10%
427.60%
2.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 24.88% vs 37.36% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 35.08% vs 49.79% in Dec 2023
About Hangzhou AGS MedTech Co., Ltd. 
Hangzhou AGS MedTech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






